Nature paper: Maximising coverage

Santaris Pharma is a leading biopharmaceutical company developing a new class of RNA medicines called RNA antagonists, using their unique Locked Nucleic Acid (LNA) technology. Santaris Pharma's RNA antagonists are being developed to silence messengerRNAs and microRNAs associated with various diseases including cancer, metabolic disorders and viral infections. A Santaris study published in Nature, demonstrated the first microRNA silencing in non-human primates. College Hill used this news to further increase media awareness of Santaris and their LNA-based therapeutics.

• To use the Nature paper to further raise media awareness of Santaris Pharma and its novel LNA approach

Our Approach

• Ahead of the publication of a paper in Nature, the Life Sciences team identified key science media to pre-brief on Santaris Pharma and its approach
• Arranged a media briefing at the Science Media Centre to key UK national journalists
• Extensive media follow up to UK and European media

• Significant national and international coverage including: BBC News, Daily Mail, Guardian, Independent, Telegraph, Times and Reuters
• Key trade media who covered the story included: BioCentury, BioWorld, Chemistry & Industry, New Scientist, Science and Scrip
• Multiple international media enquiries afterwards
• Invitations to Santaris Pharma scientists to present the data at conferences all over the world

Director, Corporate Communications at Santaris Pharma said: "College Hill did an impressive job ensuring our news was covered throughout an extensive list of UK national and trade publications. The coverage also resulted in multiple international media enquiries and invitations to present the data all over the world."

March 2008

To discuss our capability in this area please contact:
Adam Michael, Account Director
+44 (0)20 7457 2020
adam.michael[at]collegehill.com

© 2008 College Hill Associates | Registered in England No 1036926 / VAT No 245666930 | Legal

other clients